South Korea represents Asia-Pacific’s third largest biotech market after Japan and China. The country’s biotech market is dominated by major pharmaceutical corporations and smaller venture capital supported businesses. Fuelled by strong government support, increased international investments, and strong performance of the biomedicine sector, the biotech market in South Korea is forecasted to grow at a CAGR of around 21% during 2010 - 2012, says our new research report “Asia Pacific Biotechnology Market (2008-2012)”.
Our team of experts has found several factors driving growth of the South Korean biotech industry. Among several reasons described in the report, strong IT capabilities are emerging as the major growth driver for the country’s booming biotech industry. IT acts as a primary tool in biotech research in fields like, genomics and proteomics as the rising power of computers is reducing the cost of massive computations. As South Korea is already well established and advanced in terms of IT innovations, its IT capabilities are much proficient than the Asian Pacific countries. Hence, this will provide a growth momentum to its biotech market.
Our report has included detail profile of various Asian Pacific countries such as, Japan, China, South Korea, India etc. For each country, detail description of regulatory environment along with the growth drivers and restraints has been provided in the report.
“Asia Pacific Biotechnology Market (2008-2012)” also provides information of the key competitors in the each country along with their business information and areas of expertise. The report shows a highly concentrated structure of the market, with the top players dominating the market. It provides segment level analysis of the industry along with emerging trends that may shape up with the betterment of economic conditions. The research will help consultants, industry analysts, and vendors to get an in-depth knowledge of the current, past, and future performance of the industry. The report provides an extensive research on the recent trends of the Asian Pacific biotech industry along with impartial analysis considering the impact of financial crisis on its performance.
For more information visit: http://www.rncos.com/Report/IM138.htm |
